On August 17, PHARMARON rose 3.23% in regular trading, trading at 30.78 HKD/share, with turnover of approximately 49.52 million HKD.

On the news front, the company's board of directors is scheduled to convene on August 20 to review its first-half interim results. The company previously guided H1 revenue of 7.472 billion to 7.665 billion yuan, representing year-over-year growth of 16%-19%. Notably, new orders signed grew over 30% year-over-year, with small molecule CDMO new orders surging over 50%, underscoring strong earnings visibility ahead of the formal results announcement.

Meanwhile, the broader CXO sector rallied collectively, with GenScript Bio up 5.71%, WuXi AppTec up 4.05%, WuXi Bio up 3.9%, Insilico up 2.47%, and XtalPi up 2.74%, reflecting continued improvement in industry sentiment and ongoing sector valuation recovery driven by robust order momentum across the contract research and manufacturing space.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)